1

Platform giving patients and doctors access to promising drugs in development

Team of pharma and tech experts led by Ronald Brus3rd time entrepreneur with >$5bn of exits

Raising €10m

2

To navigate and access promising drugs & diagnostic tools, currently locked away in development

myTomorrows is a tech platform that helps millions of patients left without treatment options every year

3

Born from Personal ExperienceRonald Brus MD, Founder & CEOPrev CEO Crucell ($2.8Bn sale to J&J) and Galapagos carve-out (NASDAQ $2.5bn)

Robert Kraal COOPrev COO Adyen (>$4bn), Google & DocData

Claire Harrison, General CounselPrev Slaughter & May, De Brauw, Aescap Venture

Govert Schouten PhD, Co-founder & CBO Prev CEO Mucosis

Erdem Yavuz. Co-founder & CFO Prev ING bank, Kempen & Co, Siemens AG

Mark EvansBalderton Capital

Axel HeinemannSr Partner BCG Healthcare

James Shannon(ex GSK & Novartis boards)

Erik HovingCTO KPN Group

Antoine PapiernikSofinnova Partners

Johan KleynJonesDay

Sander Nagtegaal CTOPrev Albumprinter (acquired by VistaPrint), founder Peecho

+25 FTEs on 4 continents

4

Drug access today: A $40bn market that isn’t working

Face unmet medical needs

Lack information around latest drugs & diagnostics

95% can’t access clinical trials

Don’t have resources or expertise to deal with complex early access regulation

Patients & Doctors Pharma Innovators

Struggling with increased public pressure to release drugs

Frustrated with traditional clinical trials process

Cannot afford to get new drug to market alone

Don’t have resources or expertise to deal with complex early access regulation

5

All countries have early access laws But these laws are rarely employed due to complexity

We offer navigation tools to search >80K ongoing clinical trials and access to promising drugs in development through a tech-enabled platform. In full compliance with local regulations

Serving the 95% that cannot get into clinical trials

myTomorrows is a platform connecting patients + doctors and promising new drugs

6

Search databases for Diagnostics tools, >80K ongoing Clinical Trials and Early Access Programs

Find potential treatment through geo sensitive catalogue compliance filters

Doctor verification

Engagement funnel & fulfillment

More disclosure behind log in

Technical product

Gathering Data for Patients, Doctors and Drug Developers

Clinical trials search data

‘Notify me’ alerts harvesting for drugs not on platform yet

Prescribing patterns, cohort analysis

Geographic breakdowns

Trend analysis and predictive tools

Real world evidence, analytics

Social listening & Profiling

8

• Identify potential partners using expert networks and online demand measurements

listen analyse sign engage

A sourcing playbook with 16 new products in 2016 pipeline

• Test viability of drug based on existing user base and broader demand as well as early access success characteristics

• Negotiate exclusive contracts by geography to distribute drugs for early access

• Unique payment model of revenue share and royalties

• On- and offline playbooks developed to raise awareness

• Utilizing social media channels to connect doctors, patients and drugs for the first time

9

Drugs signed last 12 months

Onc

olog

y /

hem

atol

ogy

CN

S &

Oth

er

Breast Cancer€20K/course

Lymphoma, €25K-€75K/course

Leukemia€25-€50K/course

GvHD€20-€40K/course

Colon Cancer&NSCLC€15K/course

Liver cancer€15K-€20K/course Major Depression

€4K/yr

Multiple Sclerosis€20K/yr

Chronic Fatigue€45K/yr

Heart Failure€40K/treatment

Sickle Cell Disease€17K/yr

10

Mutually Reinforcing Network Effects

Enriched DataEnhanced Commnity

More & Better DealsWith Biopharma

Shorter Contract Cylces& Time to Listing

More Drugs &Diagnostics

More Case Studies& References

Traffic

Brand Awareness

More Doctors, Patients& other Users

ENRICHED DATAENHANCED COMMUNITY

Improved MarketplaceServices

SUPPLY DEMAND

11

€10Bn includingregulation

arbitrage€20Bn

incldeprioritized

assets

€40Bnas awareness of

early access mechanisms

become widespread

myTomorrows <1% of smallest segmentin untapped market

€3Bn traditional

early access

TAMOur platform is the first step to bringing the $40bn development drug market online

12

Product Forecast

2015 actual 2016 2017 2018

Biotech Products7 products

(from 5 companies)

12 products(2/3 from new co’s)

20 products(3/4 from new co’s)

40 products(3/4 from new co’s)

Big Pharma Products 0 1 product 3 products

20 products(from 4-5 co’s)

Diagnostics 2 products3 products(from 2 co’s)

10 products(from 8 co’s)

20 products(from 15 co’s)

13

Tech roadmap

2016 2017

Features Data gathering

Enhanced localization

MeSH taxonomy (data)

Mobile apps for HCPs and Patients

Patient profiling EAP

RWE: recruitment CT & EAP

Adverse event reporting

Social listening & Sentiment analysis

Patient Reported Outcome

14

Dual revenue model

REVENU

E

YEARS

FDA Approval

0 1 2 3 4 5

Revenue share (30%) Royalty share (5%)REVEN

UE

YEARS

FDA Approval

0 1 2 3 4 5

Country 1

15

Under the RadarSign first Biotechcontract

POC Price Point/Country

Large PharmaGrowth EU, LatAm, ME

2012/13 2014 2015 2016

+US +Asia

2017

Revenue streams Pre-Approval drugs

Pre-Approval drugs

Pre-Approval drugs

Diagnostics

Pre-Approval drugs

Diagnostics

GROW

2018

Pre-Approval + Approved

DiagnosticsCaaSData

Top Line €45K €2.1m €… €.. €..

Leverage Scale on all Fronts

2019

Pre-Approval + Approved

DiagnosticsCaaS

RoyaltiesData

€..

Offline Offline Offline Offline + Online 75% Online 90% Online 95% Online

GMV / Roll-out

16

Market Adoption

15 products signed. Drug developers adding additional products on platform

Active in 17 countries

Started POC sales April 2015, €27KSales FY2015 €2.1m

17

On the way…Slash drug prices by 40% through earlier market access

Large Pharma reliant on less drugs at higher price points

4-5yrs earlier commercial access will slash price point required for DCFs to remain attractive

18

Proposition

First online mover, adding critical mass

Technology enriched at every layer

Raising €10m Proven, de-risked model

Onboarding doctors & patients at fraction of cost vs traditional model

Team backed by leading VCs and stakeholders